TR-1: Notifications of Major Interests in Shares
1. Identity of the issuer or the underlying FINSBURY WORLDWIDE
issuer of existing shares to which voting PHARMACEUTICAL TRUST PLC
rights are attached:
2. Reason for notification (yes/no)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments which may result
in the acquisition of shares already issued to which voting rights
are attached
An event changing the breakdown of voting rights
Other (please specify):An update in the total voting rights
triggered this notification
3. Full name of person(s) subject to BRITISH EMPIRE SECURITIES AND GENERAL
notification obligation: TRUST PLC
4. Full name of shareholder(s) (if JP MORGAN --- CHASE NOMINEES LIMITED A/
different from 3): C CREST BT01C
5. Date of transaction (and date on 24 APRIL 2009
which the threshold is crossed or
reached if different):
6. Date on which issuer notified: 28 APRIL 2009
7. Threshold(s) that is/are crossed or 4%
reached:
8: Notified Details
A: Voting rights attached to shares
Class/type Situation Resulting situation after the triggering
of shares previous to the transaction
triggering
If transaction
possible
use ISIN
code
GB
0003385308
Number of Number of Number of Number of voting Percentage of
shares voting shares rights voting rights
rights
1,948,117 1,602,784
1,948,117
Direct Indirect Direct Indirect
1,602,784 3.978%
B: Financial Instruments
Resulting situation after the triggering transaction
Type of Expiration Exercise/ No. of voting Percentage of
financial date conversion rights that may be voting rights
instrument period/date acquired (if the
instrument
exercised/
converted)
Total (A+B)
Number of voting rights Percentage of voting rights
1,602,784 3.978%
9. Chain of controlled undertakings through which the voting rights and /or the
financial instruments are effectively held, if applicable:
Proxy Voting:
10. Name of proxy holder:
11. Number of voting rights proxy
holder will cease to hold:
12. Date on which proxy holder will
cease to hold voting rights:
13. Additional information:
14 Contact name: PHOENIX ADMINISTRATION SERVICES LIMITED
--- COMPANY SECRETARY
15. Contact telephone name: 01245 398950
Annex: Notification of major interests in shares
A: Identity of the persons or legal entity subject to the notification
obligation
Full name BRITISH EMPIRE SECURITIES AND GENERAL
TRUST PLC
(including legal form of legal
entities)
Contact address PHOENIX ADMINISTRATION SERVICES LIMITED
--- COMPANY SECRETARY
(registered office for legal entities)
SPRINGFIELD LODGE
COLCHESTER ROAD
CHELMSFORD
CM2 5PW
Phone number & email 01245 398950
Other useful information
(at least legal representative for
legal persons)
B: Identity of the notifier, if applicable
Full name MARK POPE
Contact address FROSTROW CAPITAL LLP
25 SOUTHAMPTON BUILDINGS
LONDON
WC2A 1AL
Phone number & email 0203 008 4913
mark.pope@frostrow.com
Other useful information FROSTROW CAPITAL IS THE COMPANY
SECRETARY TO THE FINSBURY WORLDWIDE
(e.g. functional relationship with the PHARMACEUTICAL TRUST PLC
person or legal entity subject to the
notification obligation)
C: Additional information
S:\FWPT
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.